Menarini group, is a leading international pharma and diagnostics company, with presence in over 140 countries. It is focused on therapeutic areas viz. cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation and analgesia. For FY23, revenues from the target portfolio products stood at Rs 32.2 crore.
In a regulatory filing, Lupin said, ?The company has signed an agreement to acquire five legacy brands in strategic therapy areas - gastroenterology, urology and anti-infectives from Menarini (A. Menarini India and A. Menarini AsiaPacific Holdings Pte), along with the associated trademark rights.?
The five brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).
The pharma company said that it has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A. Menarini India.
This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India, it added.
These legacy brands help the company in further enhancing its diverse portfolio and solidifying its position as a leading pharmaceutical organization in India.
?The acquisition is of brands along with the associated trademark rights and not of any unit or division of Menarini,? Lupin stated.
Nilesh Gupta, managing director, Lupin said, ?This acquisition aligns well with our strategic goal to broaden our presence in the Indian market. By offering a comprehensive range of products, our aim is to deliver even greater value to our stakeholders and the communities we serve.?
Rajeev Sibal, President - India Region Formulations, Lupin, said ?Growing urbanization and dietary changes are driving the demand for gastrointestinal and urology treatments in India. This acquisition strengthens our presence in India and bolsters our therapy pipeline.
Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The company reported consolidated net profit of Rs 452.26 crore in Q1 FY24 as compared with net loss of Rs 89.08 crore in Q1 FY23. Revenue from operations jumped 31.58% YoY to Rs 4,742.12 crore in Q1 FY24.
Shares of Lupin slipped 2.66% to Rs 1,098.95 on the BSE.
Powered by Capital Market - Live News
Beware of fraudulent tips, unauthenticated news and advice on stock market.
At BOB Capital, your account security is our topmost priority. Beware of receiving fraudulent communications, unauthenticated trading tips and unsolicited calls on trading in stocks from unverified sources, received through Whatsapp, Telegram, SMS, Calls, etc and take an informed decision before investing.
What should you do if you receive a trading tip over phone or SMS?
Report unsolicited messages to the Stock Exchange on +91 8291833676 or on designated email id i.e. feedbk_invg@nse.co.in. Please visit here to understand better.
Please visit CVC website at pledge.cvc.nic.in and take "Integrity Pledge" to be an active part of the "Satark Bharat, Samriddh Bharat" (Vigilant India, Prosperous India).
Filing complaints on SCORES - Easy & quick: a. Register on SCORES portal scores.sebi.gov.in/ b. Mandatory details for filing complaints on SCORES are i. Name, PAN, Address, Mobile Number, E-mail ID. c. Benefits: i. Effective communication ii. Speedy redressal of the grievances.
Valued Customer,
BOB Capital Markets Limited (BOBCaps) is firmly committed to the safety of your wealth. We would like to bring to your notice certain precautions that you certainly must take against potential tele-fraudsters/ unscrupulous and unregistered portfolio managers:
ALWAYS AVOID
We would like to caution you against such fraudulent calls and SMSes and urge you to be alert. Follow the golden rule:
Do not share your Login Credentials or Passwords with anybody
BOBCaps employees / representatives never ask for your password.
Certain tele-fraudsters / unscrupulous and unregistered portfolio managers call customers or SMS them on the pretext of providing investment tips and lure them to invest through their bogus firms by promising huge profits.
Such deceitful callers ask the customer to share his/her login credentials with passwords to allow trading in their accounts, assuring huge returns.
Often trades done in the customer’s accounts are far from the best interest of the customers. Holdings of customers are often sold and with the funds, trades are then placed in illiquid securities at unrealistic prices.
At times, the holdings of customers are sold at prices detrimental to the customer. The so-called “portfolio manager” assures profits, which naturally does not materialize. Customers are deceived into providing access to their trading accounts, thereby allowing such fraudsters access to funds and securities available to execute trades, injurious to the customer’s interest.
In our continuous effort to keep you safeguard from the market related frauds and increase awareness while conducting trades, we request you to go through the Press Release issued by the NSE and would request you to ensure that you do not engage with the individuals and entities mentioned below: